Drug

Chipscreen Biosciences Secures NMPA IND Acceptance for CS23546 – Oral Small‑Molecule PD‑L1 Inhibitor Advancing in Relapsed or Refractory Lymphoma
CancerChipscreen Biosciences

Chipscreen Biosciences Secures NMPA IND Acceptance for CS23546 – Oral Small‑Molecule PD‑L1 Inhibitor Advancing in Relapsed or Refractory Lymphoma

Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that its Clinical Trial Application (IND) for CS23546 has been officially accepted by China's National Medical Products Administration (NMPA), clearing the way…

Takeda Launches Oveporexton in Japan and China – Novel Oral OX2R Agonist for Narcolepsy Type 1 Now Commercially Available

Takeda Launches Oveporexton in Japan and China – Novel Oral OX2R Agonist for Narcolepsy Type 1 Now Commercially Available

Northland Biotech's Sedominji Completes First National Shipment – World's First Approved HGF Naked Plasmid Gene Therapy Reaches CLI Patients in Nine Provinces

Northland Biotech’s Sedominji Completes First National Shipment – World’s First Approved HGF Naked Plasmid Gene Therapy Reaches CLI Patients in Nine Provinces

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
J&J Darzalex Faspro Gets NMPA Approval for Transplant-Eligible Myeloma Patients
CancerJ&J

J&J Darzalex Faspro Gets NMPA Approval for Transplant-Eligible Myeloma Patients

Everest Medicines Files Velsipity for Ulcerative Colitis in China
Everest MedicinesHKG: 1952

Everest Medicines Files Velsipity for Ulcerative Colitis in China

Keytruda Wins 20th China Approval for Endometrial Cancer in First-Line Setting
CancerMerck Sharp & Dohme

Keytruda Wins 20th China Approval for Endometrial Cancer in First-Line Setting

ADC / XDCCancer

Hanx Biopharma HX111 ADC Begins Phase I Trial for Lymphoma and Solid Tumors

Show More